Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ping Chi

Showing results (241-250 of 264) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal TumorsPing Chi, Li-Xuan Qin, Niedzica Camacho, et al.
Nature Genetics|June 30, 2025
Disruption of TAD hierarchy promotes LTR co-option in cancerElissa W P Wong, Merve Sahin, Rui Yang, et al.
Cancer Discovery|July 5, 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral MimicryAmish J Patel, Sarah Warda, Jesper L V Maag, et al.
Nature Medicine|January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trialMichael C Heinrich, Robin L Jones, Suzanne George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Nature Genetics|January 13, 2025
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promotersNaitao Wang, Mohini R Pachai, Dan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.
Science (New York, N.Y.)|May 26, 2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targetsFanying Tang, Duo Xu, Shangqian Wang, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Pageof 27

Showing results (241-250 of 264) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal TumorsPing Chi, Li-Xuan Qin, Niedzica Camacho, et al.
Nature Genetics|June 30, 2025
Disruption of TAD hierarchy promotes LTR co-option in cancerElissa W P Wong, Merve Sahin, Rui Yang, et al.
Cancer Discovery|July 5, 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral MimicryAmish J Patel, Sarah Warda, Jesper L V Maag, et al.
Nature Medicine|January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trialMichael C Heinrich, Robin L Jones, Suzanne George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Nature Genetics|January 13, 2025
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promotersNaitao Wang, Mohini R Pachai, Dan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.
Science (New York, N.Y.)|May 26, 2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targetsFanying Tang, Duo Xu, Shangqian Wang, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Pageof 27